Upfront ASCT Still Best Option in Newly Diagnosed Multiple Myeloma

In this video we discuss the results of a phase III trial that studied upfront high-dose chemotherapy plus autologous stem cell transplantation (ASCT) compared to chemotherapy alone and bortezomib in newly diagnosed multiple myeloma.

Undergoing upfront autologous stem cell transplantation (ASCT) is still the preferred treatment of choice for patients aged 65 or younger with newly diagnosed multiple myeloma, according to interim results of a phase III trial that examined upfront high-dose chemotherapy plus ASCT vs chemotherapy alone and bortezomib.

Results of the study were presented at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, held earlier this month in Chicago (abstract 8000).

In this video Michele Cavo, MD, of the University of Bologna in Italy, discusses the results of the trial.